Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved survival and are increasingly used for non-small cell lung cancer. However, use may be limited by immune-related adverse events such as checkpoint-inhibitor pneumonitis (CIP). Literature estimates for CIP incidence are inconsistent. Real-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiu, Bruce C, Zubiri, Leyre, Iheke, James, Pahalyants, Vartan, Theodosakis, Nicholas, Ugwu-Dike, Pearl, Seo, Jayhyun, Tang, Kimberly, Sise, Meghan E, Sullivan, Ryan, Naidoo, Jarushka, Mooradian, Meghan J, Semenov, Yevgeniy R, Reynolds, Kerry L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204442/
https://www.ncbi.nlm.nih.gov/pubmed/35705313
http://dx.doi.org/10.1136/jitc-2022-004670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204442/
https://www.ncbi.nlm.nih.gov/pubmed/35705313
http://dx.doi.org/10.1136/jitc-2022-004670

Ejemplares similares